Long-term Effects of Fianlimab and Cemiplimab in Advanced Melanoma

This study focuses on understanding the long-term safety and effectiveness of two experimental drugs, fianlimab and cemiplimab, in individuals with advanced melanoma, a serious form of skin cancer. Participants in this study have previously been treated with these drugs in an earlier study. The research aims to gather information on how these drugs impact the health of patients over a longer period, which can help improve future treatment strategies and provide better care for melanoma patients. During this study, participants will not receive any new doses of fianlimab or cemiplimab. Instead, their health will be closely monitored to observe the status of their cancer and gather data on their overall well-being. The study will also collect details about any other treatments participants might have received after the previous study. This approach helps researchers evaluate the lasting effects of the drugs without introducing new interventions, ensuring a focus on long-term health outcomes.